Good afternoon, welcome to Shockwave's first quarter 2023 earnings conference call. At this time, all participants are in a listen-only mode. We will be facilitating a question-and-answer session towards the end of today's call. As a reminder, this call is being recorded for replay purposes. I would now like to turn the call over to Debbie Kaster, Vice President of Investor Relations at Shockwave, for a few introductory comments. Please go ahead. Thank you all for participating in today's call. Joining me today from Shockwave Medical are Doug Godshall, President and Chief Executive Officer, Isaac Zacharias, President and Chief Commercial Officer, and Trinh Phung, Vice President of Finance, who is standing in for Dan Puckett while he's out of the country on a much-deserved family vacation. Earlier today, Shockwave released financial results for the quarter ended March 31st, 2023. A copy of the press release is available on Shockwave's website. Before we begin, I would like to remind you that management will make statements during this call that include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call other than statements of historical fact are forward-looking statements. All forward-looking statements, including, without limitation, statements relating to our sales and operating trends, business and hiring prospects, financial and revenue expectations, reimbursement proposals, future product development and approvals, and the integration of Neovasc and its technologies into our business are based upon our current estimates and various assumptions. These statements involve material risks and uncertainties, including the impact of macroeconomic conditions and global events such as the COVID-19 pandemic, that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements. For a list and description of the risks and uncertainties associated with our business, please refer to the Risk Factors section of our annual report on Form 10-K on file with the SEC and available on EDGAR and in our other reports filed periodically with the SEC. Shockwave disclaims any intention or obligation, except as required by law, to update or revise any financial projections or forward-looking statements, whether because of new information, future events, or otherwise. This conference call contains time-sensitive information and is accurate only as of the live broadcast today, May 8th, 2023. With that, I'll turn the call over to Doug. Thanks, Debbie. Good afternoon, everyone, thank you for taking the time to join us to review Shockwave's results for the first quarter of 2023. The year started out well following a strong end to 2022. First quarter revenues of $161.1 million represented a 72% increase from the first quarter of 2022. All areas of the business contributed to our growth in the quarter, with U.S. coronary, U.S. peripheral, and international each delivering solid sequential double-digit growth in the quarter compared to the fourth quarter of 2022. Later in the call, Isaac will provide additional details from the commercial side of our business, first, I want to highlight some recent accomplishments. Last month, we announced the full U.S. commercial launch of our L6 peripheral IVL catheter on the heels of the limited launch of the product. As a reminder, L6 was developed specifically to expand the capabilities of our peripheral portfolio and, in particular, to address difficult-to-crack calcification in larger vessels such as the iliacs. The customer response to its performance and initial demand for L6 has exceeded our expectations, and it appears to offer broader utility than we had anticipated. The L6 launch also comes following a very successful launch and transition to M5+ last year, which continues to perform well in above-the-knee applications and increasingly is being used in below-the-knee vessels. C2+, our next-generation coronary product, began a full launch in international markets during the quarter and will be showcased next week at EuroPCR in Paris. C2+ offers up to 120 pulses, a 50% increase from C2, and early feedback has also been very positive on this product. We have seen C2+ being used in long, calcified segments within all ranges of calcified morphologies and complex lesion types. Our team has reported that over 70% of the cases done with C2+ have used more than 80 pulses, which indicates that the additional pulses are being used quite regularly. We are optimistic that this will lead to increased adoption of coronary IVL. We plan to launch C2+ in the U.S. early in the fourth quarter of 2023. We also added a new future growth platform last quarter by acquiring Neovasc and the Reducer system. The transaction just closed a few weeks ago, and our team is quickly getting integrated into the commercial, R&D, and COSIRA II trial activities. Our general manager of the Reducer program led the transaction and has deep experience in leading high-performing teams in the cardiovascular arena. Our clinical group is leaning in aggressively to help the legacy Neovasc team accelerate trial enrollment. We are not yet ready to update our revenue or enrollment forecasts. Our commercial focus for now is to understand what will be required to create a market for the Reducer so we are ready when we have data from COSIRA II, much as we used our early international launch of C2 to prepare for the broader global and U.S. launches. I will say that the feedback we have received from European customers who use this device commercially has been consistently very positive. As a result, we are more bullish now than we were when we announced the transaction. More to come. EuroPCR will not only serve as the public launch meeting for C2+, it will be a venue for multiple IVL and Reducer presentations. We will also be celebrating the five-year anniversary of the launch of coronary IVL. We have come a very long way in a relatively short period of time. We'll be sponsoring several symposia and training villages at PCR, where we plan to further educate physicians on IVL, in addition to covering refractory angina and how our newly acquired Reducer product plays a role for these no-option patients. While many of us will still be busy in Paris, the Society for Cardiovascular Angiography & Interventions, or SCAI conference, will be kicking off in Phoenix. A highlight for us at SCAI will be the presentation of our CAD III post-approval study from the CathPCI registry, which will reflect the real-world safety and effectiveness of coronary IVL. Lastly, on the scientific side, we had great attendance at our CRT symposium back in February, where the main IVL focus was the impact of calcified nodules on two-year clinical outcomes after IVL-assisted coronary stenting. As our data matures, it continues to demonstrate that IVL is equally effective across the full spectrum of calcified lesions, whether circumferential, eccentric, or nodular. As we continue to generate compelling data that supports broader use of IVL, our R&D team keeps paving the way for future growth with our expanding pipeline. We have discussed our intention to launch two new products per year, and we have also talked about our plan to have seven different devices by 2026. We plan to lay out our product roadmap in a bit more detail later in the year at our Investor Innovation Event, which we'll be holding on October 23rd in San Francisco during TCT. Finally, on reimbursement, CMS issued its proposed fiscal 2024 Inpatient Prospective Payment System, or IPPS document for hospital inpatient procedures in April. The proposed rule included three new DRGs specific to IVL. Two of the new DRGs would pertain to coronary IVL cases involving the insertion of a stent with and without comorbidities, and the third new DRG would cover all coronary IVL cases that do not include a stent. The proposed dollar values associated with these new DRGs seem entirely appropriate given the resource intensity of treating the extremely complex calcified anatomies that comprise the universe of patients IVL addresses every day. We look forward to the final inpatient rule likely later this summer, which will then become effective October 1, 2023. Our strong 1st quarter performance suggests that we will deliver results in a higher range than our prior guidance. We now anticipate top-line revenue in the range of $700 million-$720 million for the full year of 2023, representing growth of 43%-47% from 2022. This guidance does not contemplate any revenue contribution from the Reducer, which we expect will be less than $5 million for the balance of 2023. I will turn the call over to Isaac to provide more color on the commercial front. As Debbie noted, Dan is on a long-planned and well-earned vacation with his family, and we are delighted to have Trinh with us today to discuss the details of our financial results after Isaac. Isaac? Thank you, Doug. The team posted another strong quarter across U.S. coronary, U.S. peripheral, and our international business. U.S. peripheral revenue was up 12% from last quarter and once again almost doubled from a year ago. Growth was driven by solid usage across three peripheral products and all vessel beds. In the U.S., we have fully transitioned to M5+, have steadily increased below-the-knee business with S4 and increasingly M5+, and are off to a very encouraging early start to the L6 launch. Our launch strategy for L6 is consistent with what has worked for our other product launches. We expect to launch accounts in a very controlled, deliberate manner to help ensure that customers understand when and where to use L6. We also plan to use the L6 launch period to reinforce appropriate use of our other products. L6 is designed specifically to treat larger peripheral vessels of the iliac and common femoral arteries. Our engineers were able to achieve delivery of a more uniform high-energy profile to these large vessel lesions by developing a compact emitter array that is distinct from our other products. In addition to the improved energy profile, the larger diameter balloons are better able to facilitate energy delivery and dilate up to the target vessel diameter. The results in clinical practice are surprising us and our customers. What we are hearing most often is how impressed physicians are with the angiographic results after L6, noting in many cases that the artery looks as good as if it were stented. We are pleased with the clinical utility and are seeing strong utilization across the sizes. About 60% of L6 cases are coming from the new sizes offered, 9 mm, 10 mm, and 12 mm, suggesting that we may see some incremental penetration into procedures that M5+ could not optimally address. In addition to a strong clinical value proposition, L6 carries a strong economic value proposition for hospitals. First, IVL is clinically indicated for use in iliac arteries, whereas this is not the case for many of the atherectomy devices. Second, reimbursement is not consistent for atherectomy. In contrast, IVL carries additional reimbursement in iliac arteries that adequately covers hospital costs to acquire L6. U.S. coronary revenue grew a solid 11% sequentially from Q4 and 57% compared to the prior year. Average daily sales increased 10% sequentially from Q4 and 54% from a year ago, driven primarily by increased penetration into our existing accounts. As anticipated, new account additions continued to decline as we only added about 60 new accounts in the first quarter. The strong growth in our U.S. coronary business in Q1 is a sign that the key activities we initiated in the second half of last year are succeeding. We have been able to increase penetration of coronary IVL in our accounts with nearly 99% of Q1 2023 U.S. coronary revenue coming from accounts that were launched before 2023. I will take just a minute to remind you of the activities that we believe have worked to drive deeper penetration of coronary IVL. First, we ended the quarter with 90 territories and about 1.9 clinical specialists per territory. We plan to continue optimizing our structure, adding territories, and increasing the clinical specialists per territory throughout this year. Together, this strategy enables us to spend more time with physicians to help train them and then reinforce when they should be appropriately using IVL. The time our team spends in the hospitals drives increased penetration for both coronary and peripheral. On the international side, we posted record revenue that was almost double our year-ago performance, with strong results in all of our international markets. Sales of coronary and peripheral products both grew over 80% from a year ago, we had a solid start for our newly launched C2+ catheter. Peripheral momentum is growing internationally as we have increased our marketing resources substantially. We now have very focused efforts that are supported by KOLs to foster peer-to-peer education. Similar to L6 and the other launches you have seen us execute, our C2+ launch follows our strategy of a methodical launch, targeting high-volume accounts, going deeper, and spending time educating each account. It is early in the launch, but the team is very encouraged about the feedback they are getting so far. Geographically, we saw particularly strong growth for our coronary businesses in Germany and Japan. In Germany, the change in January to reimburse coronary IVL procedures at higher-paying DRGs, combined with the launch of C2+, have been a game-changer in the first few months. As you know, German hospitals are very focused on economics, and IVL was margin-negative in most cases prior to January of this year. Despite being on the market for nearly five years and being represented by a strong direct sales team, coronary IVL penetration in Germany is only about 1%, which is far lower than any other Western European country. We look forward to continued growth in Germany as we expand our team to better service and educate physicians on the use of IVL. I expect that our penetration in Germany will go from the lowest to the highest amongst Western European countries. Our launch in Japan is going very well. We are already seeing solid use of IVL in our launched accounts, with strong penetration in high-volume centers propelled by enthusiastic physician support. We plan to continue building that team and adding sales reps, field marketing professionals, and additional support functions to further accelerate adoption in Japan. We are encouraged by the early success our teams are achieving this year in Germany and Japan, markets where reimbursement for IVL is adequate and economic considerations are well addressed. We believe this is a positive indicator for potential increases in penetration in the U.S. as the long-term reimbursement picture for coronary IVL is beginning to come into focus over the course of this year. We have seen the first of three proposed rules for U.S. reimbursement in 2024 read out, with the IPPS addressing the hospital inpatient setting. This summer, we hope CMS chooses to address coronary IVL in the outpatient setting in 2024, and we remain bullish about the long-term picture when they do. Until then, TPT covers the hospital's device cost. We also know that a new CPT code for coronary IVL will enable physicians to receive incremental payment for the first time for any of our therapies. This summer, we will see what incremental payment CMS will propose for those physicians. We have worked to create an environment where the incentives for the patient, physician, and hospital are all aligned. The goal for the patient is to have IVL treatment for their calcified PCI because it's very safe and helps ensure a better result. The physician shares this goal, particularly when they are receiving incremental payment for the additional work of using IVL. The hospital wants the patients to get the best therapy and is further motivated when the procedures have positive economics. We have early evidence of what IVL penetration can be when these incentives are all aligned from the early and very encouraging adoption rates we have seen thus far in Japan. With that, I will turn the call to Trinh to review the financials. Thank you, Isaac. Good afternoon, everyone. Shockwave Medical's revenue for the first quarter ended March 31, 2023, was $161.1 million, a 72% increase from $93.6 million in the first quarter of 2022. U.S. revenue was $131.6 million in the first quarter of 2023, growing 68% from $78.5 million in the first quarter of 2022. Our coronary product contributed $90.9 million to U.S. revenue in the quarter. U.S. revenue from our peripheral products was $40.5 million in the first quarter of 2023. The growth in U.S. revenue reflects the increased utilization at existing accounts, new account adoption of IVL, and continued salesforce expansion. International revenue was $29.4 million in the first quarter of 2023, representing a 95% increase from $15.1 million in the first quarter of 2022. Our coronary product contributed $23 million to international revenue in the first quarter of 2023. International revenue from our peripheral products was $5.6 million in the first quarter of 2023. The increase in international revenue over the prior year period reflects continued geographic expansion, including China and Japan, growth in customer demand, and the growth of our direct sales force in Europe. Looking at product lines, our peripheral products, Shockwave M5, Shockwave M5+, Shockwave S4, and Shockwave L6, accounted for $46.1 million of total revenue in the first quarter of 2023, compared to $22.9 million in the first quarter of 2022, a 102% increase. Our coronary products, Shockwave C2 and Shockwave C2+, accounted for $113.9 million of total revenue in the first quarter of 2023, compared to $70.3 million in the first quarter of 2022, representing a 62% increase. In addition, the sales of generators contributed $1.1 million in revenue in the first quarter of 2023, compared to $0.4 million in the first quarter of 2022. Gross profit for the first quarter of 2023 was $140 million, compared to $80.7 million in the first quarter of 2022. Gross margin for the first quarter of 2023 was 87%, as compared to 86% in the first quarter of 2022. The improvement in gross margin was primarily driven by product mix, as well as continued improvements in productivity and process efficiencies. Total operating expenses for the first quarter of 2023 were $100.2 million, a 53% increase from $65.4 million in the first quarter of 2022. Sales and marketing expenses for the first quarter of 2023 were $54 million, compared to $36 million in the first quarter of 2022. The increase was primarily driven by sales force expansion. R&D expense for the first quarter of 2023 were $27 million, compared to $17 million in the first quarter of 2022. The increase was primarily driven by headcount growth. General and administrative expenses for the first quarter of 2023 were $19.2 million, compared to $12.4 million in the first quarter of 2022. The increase was primarily driven by higher headcount to support the growth of the business. Net income for the first quarter of 2023 was $39.1 million, compared to a net income of $14.5 million in the first quarter of 2022. Basic net income per share for the period was $1.07. Diluted net income per share for the period was $1.03. We ended the first quarter of 2023 with $416.9 million in cash equivalents, and short-term investments. At this point, I would like to turn the call back to Doug for closing comments. Thank you, Trinh and Isaac. We are encouraged that our vision of sustained high-end growth in all categories and geographies which was achieved again last quarter, and we see little reason for that to stop anytime soon. Well done by our global team. We look forward to reporting on their continued achievements in upcoming quarters. With that, we can open the call for questions. At this time, we will be conducting a question and answer session. If you would like to ask a question, please press star one on your telephone keypad. A confirmation tone will indicate that your line is in the question queue. You may press star two if you would like to remove your question from the queue. We ask that you limit your questions to one and a follow-up so that others may have an opportunity to ask questions. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. One moment please while we poll for questions. Our first question comes from Adam Maeder with Piper Sandler. Please proceed with your question. Hi, good afternoon, Doug and team, and thank you for taking the questions. Congrats on a great start to the year. Doug, I apologize for asking this upfront, but feel compelled to ask, is there anything more that you can say or anything you can say on the media reports about deal interest from Boston Scientific? Were you approached, and any comment on the status of those conversations? Yeah, it's our policy not to comment on speculation. We will continue to not comment, but appreciate the question. Okay. Fair enough, Doug. Worth a shot there. Maybe I can ask about the guidance. $700 million-$720 million, a healthy guidance raise of $40 million over the previous guide. You beat Q1, I think, by $14 million. Maybe just talk about what gives you the confidence to raise by that amount at this juncture in the year. Then if you could also just kind of walk us through a little bit about the construction of the guidance in terms of, you know, coronary versus peripheral, U.S., OUS, et cetera. Then I had a follow-up. Thanks. Isaac and I will tag team on this. You know, the I know there was angst in the fourth quarter, when there was some unusual procedural softness in October, and we felt pretty confident that that was an aberration, not a trend. This year it's proving that we were right to believe that. The year has started out from a procedure basis, quite well, globally. We're also very encouraged that the investments we may have been making and will continue to make through this year, particularly in the U.S. on penetration are already starting to show dividends, whether that's the increase in educational programs or expansion of our clinical specialist team. The increased utilization both in coronary and peripheral are taking shape nicely, and we believe that that's going to continue through the year. We're assuming some modest impact of the IPPS in the fourth quarter of this year on coronary. Internationally, as Isaac indicated, Japan's off to a very encouraging start. Germany, the benefits of improved payment, is also proving out and the smaller but improving traction that we're seeing on peripheral internationally is encouraging, although the contribution is meaningfully less than the others just because it's starting from a smaller base. Okay, perfect. That's great color. I don't know if Isaac has anything to add, otherwise I can move on to the follow-up. Yeah, I'd add that we really like what we're seeing in the first quarter from the L6 launch early stages, C2+ early stages. The other part of your question, I think from a composition standpoint, it's the mix geographically and by product is gonna be reasonably consistent in our updated guide, but we won't break it out. Okay, that's helpful color, guys. Thank you for that. Maybe just one quick one on reimbursement, actually asking about the outpatient rule for calendar 2024 and the transition around your passthrough payment next year. You know, you gave very helpful remarks on the last earnings call and talked about confidence and, you know, a smooth transition, we'll call it. Just curious if you had any updated views or thoughts or if anything's kinda changed since that last update we got. Thanks so much for taking the questions, and congrats on the great start. Thanks. No, no change because we don't have news to report at this juncture. That won't be until the proposed rule comes out this summer. I would say it is, it was a pleasant surprise to see CMS's proposed rule for IPPS to generate new DRGs, and that wouldn't have happened if we didn't have the NTAP because they wouldn't have been able to identify IVL-only cases on the inpatient basis. I think there's a potential read-through that one could take that CMS did what they do. They looked at the math, and the math said that they needed to structure new DRGs. That's a lot more work for them than would be required to slot us into the 5194 APC that we've suggested, and they'll once again have a code that they can track with the Transitional Pass-Through. If they look at the costs associated with IVL outpatient procedures, and they do the math just like they did the math for inpatient, we continue to be highly confident that they will land in 5194. Timing is still in their hands. Given that they moved early and aggressively on inpatient, we think first half of next year, either January or July, seems the more likely outcome. Thanks for the color. Our next question comes from Bill Plovanic with Canaccord Genuity. Please proceed with your question. Great. Thanks. You guys, congratulations. You make it tough to ask questions 'cause you give us so much information. I'm gonna try to. You don't have to ask many. You don't have to ask many, Bill. Oh, no. We have to preen as sell-side analysts. That's our job. My questions are really more into Japan and China. Just, m aybe you said something on China, and I missed it on that answer, but kinda curious how is China coming back for you and the rebound there. On China, I think you know, you had so much success in the US so early, which I think surprised a lot of people on the coronary device. Trying to understand, can you compare and contrast maybe the infrastructure and scale of the commercial organization in Japan today, and kinda how should we expect that to scale up over the next year or two, and kinda maybe relative to where were you when you launched coronary in the U.S.? maybe that'll help us get a better feel for how coronary can launch in Japan. Thanks. Sure. Thanks for the questions, Bill. China, yeah, the, you know, as others have reported, COVID, when they opened up and, you know, COVID swept through just about everywhere in four weeks, it was done. There was a, you know, very soft January in China, between that and the new year. We've seen, you know, kind of paces and they track our, you know, we track cases at the JV. What we've seen on the case level is really nice, steady uptick in cases being done with coronary by week. Same is true of peripheral, but peripherals, you know, coronary is like everywhere outside the U.S., a relatively large chunk of the business is coronary compared to peripheral. We're pleased with the way China has, you know, kind of started the year. February, March, April, things are going well. They've got provincial listings in place, which took a long time, you know, to kind of cycle through and then getting product on the shelf and training, and the cases will keep coming. Really pleased with what we're seeing in China this year. On Japan, the launch has started very well. It's, you know, kind of similar to how we've launched elsewhere, in terms of trying to get the accounts trained well, making sure that they can do cases, and understand how the product works and when it's most appropriate. The physician excitement is really high. I think as we go through the year, we'll see a lot more publications and podium presence in Japan with Shockwave, which will help build momentum. From a team standpoint, we have a much smaller team there than we had in the U.S. when we launched. The dynamic of that is in the U.S., we've been selling peripheral IVL for three plus years by the time we launched coronary. Many of the physicians who were buying or using peripheral IVL were interventional cardiologists who were doing it either for peripheral interventions or for large bore access. The familiarity with the product was very high compared to what it is in China. The generator base and the installed base was very high compared to what it was in, than it is in Japan. The team in Japan is relatively smaller than the team in the U.S. I think, you know, those are the structural elements that'll make the launch in Japan slower than the U.S. It's still gonna be, I think, a very good launch and a steady ramp-up. With the reimbursement in place for both physician fees and hospital reimbursement for purchasing the device from day one, I think, you know, Japan will start kicking up pretty quickly, more slower than the U.S., but over time, you know, call it six, 12, 18 months, just be a nice, really solid momentum build there. Great. Thanks for that. If I could ask on Neovasc. Just I think, Doug, what you said, the strategy really is kinda maintain the support you've had internationally. I mean, given the guidance of $5 million, I think they're running maybe $10 million a year annualized. It sounds like you'll kinda support what's going on but not invest in that. It'll be more of a focus on the pivotal trial and kinda driving that to completion and getting data and then really taking that data and driving it. Is it? Did I hear that correctly? They weren't running at 10. I think there was an analyst who had them running at 10. Once we dug in, it was, well south of $5 million run rate. We are allocating, sort of as a career opportunity, a couple of our very strong commercial folks onto the program to help both support existing customers as well as most importantly, determine what's the right way to sell this product. How do we sort of do the early market development in Europe, much as we did in with C2 when we launched in Europe, learn from that. As our data matures from COSIRA II, which is a very sophisticated trial, and we think will have global impact, both in terms of confirming for potential customers how well the device uses, but also confirm for payers that reimbursement is appropriate. We think that the data from that trial is what will enable us to really put sort of drive revenue in a more meaningful way. We're in market development, market creation, procedure creation, and champion development mode today in limited cases in certain countries, like there is reimbursement in the U.K., there's some reimbursement in Germany. Going into countries where there is no reimbursement, is probably not gonna be a very productive use of our time, and so we're not, we're not going to, sort of try to push water uphill. As we, start to turn the card on the data, then we will, have a very good appreciation for how to effectively commercialize in the U.S., and, as we generate reimbursement in other countries to do so internationally. You can add more. No, I think that's right. The team, you know, our team is getting their arms around the commercial footprint, that Neovasc created, and it's a relatively large footprint geographically. We need to go back through and see, as Doug said, where do we think it makes sense to invest in marketing, selling and in this product and building centers of excellence, today? Then where doesn't it make sense today, but it, you know, as we get more data and turn over COSIRA II data, obviously a lot of geographies will make sense in the future. I just think we need to rationalize the activity that was being done, and we're in process of doing that. Excellent. Thank you. Our next question comes from Travis Steed with Bank of America. Please proceed with your question. Hey, congrats on a nice quarter. I wanna go back to the guide raise versus the Q1 beat. you know, it's $14 million beat versus street guidance going up $40 million. A much bigger raise. Maybe is that something you're seeing in April, you know, how the procedure environment in Q1 progressed? I don't know if things were just getting better over the course of Q1 and things are even better in April. Just kinda curious if you could comment on the general procedure environment and PCI volumes over the course of Q1. It was. The nice thing about Q1 is it was not, procedure volume was, outside of China, procedure volume was healthy and steady through the quarter. It's not like March rescued the quarter. It was a good steady cadence. We're not seeing that falter here at all, heading into the second quarter. We feel confident in the underlying procedure, and we feel confident that the meaningful disruptions caused by COVID and staffing shortages and the like, we think those are behind us. Staffing will be a continued challenge, but it's gonna be sort of in that's in the comps already. I think the comps on staffing are probably worse than they're gonna be going forward as hospitals have largely sorted through the issues and seem to be able to have figured out how to manage their staffing more effectively than they could with the uncertainty around COVID. As we sort of walk through new product launches, L6 and C2+, increased staffing on our end as we continue to add sort of high caliber clinical specialist territory managers in the U.S. Continued performance which is very encouraging in Japan and Germany and China. We sort of have multiple tailwinds that make us really, really quite confident in the prospects for the rest of the year, which made us comfortable with this level of a guide. That's helpful. Thanks, Doug. Then, a quick follow-up on the reimbursement, the inpatient reimbursement codes, maybe help us understand how that impacts the business in terms of revenue and potential there. Then, I'll ask the Op margin question as well in terms of the Q1, obviously a strong 25% almost Op margin versus the 22%-23%, where the Street was kind of at for the full year. It seems like things are progressing really well there. Just making sure we should think that flowing through for the rest of the year as well. The one caution on the balance of the year, we only had a small sort of deal cost of Neovasc embedded in Q1. We remain comfortable with the sort of $30 million for the ensuing three quarters, Q2, Q3, and Q4. That is a drag on our margin that wasn't really present in the first quarter. So we're anticipating being a bit lower than we were Q1, as you sort of load that in. In terms of the balance of the year then going forward, we feel good about how our resources are flowing other than the sort of the one time, or I guess the bogey of Neovasc. Then on the inpatient reimbursement impact on the guess about the inpatient proposed rule and how that would influence our guide, it's positive. We're not gonna break it out, but I think it didn't hurt our confidence that the rest of the year is gonna be strong. I think, you know, it's an opportunity for us to go talk and message about that with our customers. And, you know, and do that in conjunction with the C2+ launch, you know, kinda coming in the third quarter. So it's really a positive development. It'll give us, you know, a nice little thing to talk about in addition to C2+, and then we'll see, you know, where the proposed rule is in July for the physician payment and what CMS decides to do with the outpatient APC designation. As we've seen in the past, when we saw this with the above-the-knee reimbursement last year, when this goes into effect on October 1st, we will have had a few months of foreshadowing, but it's not like hospitals respond the next day and double their volume. It's, it's a positive, but it's not an immediate change in the slope of the curve. Yep. Makes sense. Thanks for the questions. Our next question comes from Larry Biegelsen with Wells Fargo. Please proceed with your question. Good afternoon. Thanks for taking the questions, and echo my congratulations on a good start to the year here. Doug, you know, we know you won't comment on rumors, but I'd love to hear how you think about maximizing shareholder value and balancing an immediate reward today, you know, versus your potential future earnings power? Yeah. We love our business. It's really, more than anything, I love the way customers respond to our product and the people that work here. Our job is to try to create great technologies that fundamentally improve and the outcomes for patients and make these procedures more satisfying and fun for our customers. That's our. We think if we do that, then the shareholders will be rewarded. If there ever came a day when somebody felt like they wanna make an offer that our board should consider, you know, our. We have a very professional board, they'll do their jobs. We're very focused on the task at hand of trying to create as strong a company as we can. That's helpful. Just for my follow-up, you know, what are the positives and negatives of being a single product company? Are there opportunities at least, you know, mainly a single product company? I know you have Neovasc now. Are there opportunities you can't achieve because you don't have a larger presence in the cath lab or you don't have greater geographic reach? Thanks for taking the questions. We're in 68 countries. I think it's 68 countries now, so there aren't many left that we are dying to get into, so we feel like we're when we find a country. The ones that are left, you die if you wanna do them. We feel pretty good about our geographic reach. And what we've witnessed from our global sales team is, I think there's been tremendous benefit of from the focus. Like, every day we wake up and we have to find a way to be successful with the devices we have, and to make them better so that we continue to feed the sales team and take advantage of the significant unmet need that still is out there. We're just really scratching the surface, whether it's peripheral or coronary, U.S. or international. We discovered Neovasc as we were out looking for other potential great ideas. We think we really got lucky, frankly, that we found one that was under-resourced by nature of the sort of financial constraints that faced via Neovasc. There were some really great people on the team. When you talk to customers, I've been in Europe two times over the past two months. I am so much more excited than I was when we bought it, because when you talk to these guys, they consistently say this device really works. They see a dramatic improvement in the outcomes for their patients with angina, for whom they've tried things for years and years. Nothing works. Both the products we have today, the products that we have in development, internally at Shockwave, and now with the addition of Neovasc, gives us really high confidence in sustained growth for many years to come. We don't, we don't see our current situation as challenged by any means as long as we execute. I just punctuate that, Larry, with, you know, we're able to grow the business still at decent growth rates while investing in global marketing, sales resources, investing in facilities, not just here in California, but in Costa Rica, and investing a lot of money in R&D and still delivering, you know, enough EBITDA to be able to make us a strong, healthy company that can go be acquisitive when we want to. It really doesn't feel like we're hampered in any way to us. All right. Thanks for taking the questions, guys. Yep. Thanks, Larry. Our next question comes from Mike Polark with Wolfe Research. Please proceed with your question. Hey, good afternoon. Thank you for taking the questions. I have two, both on reimbursement, inpatient. I wanna ask about the CPT code. On inpatient, the last call, a lot of great detail from Rob and co on just the pathway here. The message on inpatient was they look for PCI, device selection doesn't drive payment. As I look at this proposal, it would appear to me, as a dumb person on the outside, that device selection perspectively, you know, may drive payment now for PCI, specifically your product. I'm just looking to better understand how massive of a potential shift this is if this is finalized. I mean, is it too much of a stretch to call this a game-changing proposal in inpatient? Your perspective on that would be great. Kind of also looking for, you know, how much risk do you perceive here in the comment period around this proposal, these new DRGs getting finalized? Our view has always been that because outpatient procedures are associated with specific technology, that that is where customers they focus on outpatient reimbursement because they know if you use atherectomy, it's one payment, if you use stents, it's another payment. There's a technology linkage to the level of payment. Since that never previously existed for inpatient, we all get thrown into the same bucket, the payment is all determined by the complexity and complications that the patient endures. That may not be true, assuming this IPPS rule comes through later this year, in which case it's both the patient condition and whether or not they IVL is used on them. We'll see, but we may have to amend our view because now in this, in the sole case of IVL, it might matter what device you use on a inpatient and in which case then there would be a technology linkage, at least in our case, for those inpatient payment levels in their. It certainly isn't gonna be harmful to be able to combine physician payment once CPT comes through, inpatient uplift in payment and being on par on the outpatient side. Helpful. The follow-up on the CPT proposal, can you just level set, where does the baseline payment sit and what might this proposal look like? Thank you so much. Yeah. We, right now, physicians, and it varies obviously by country and payer, etcetera, but think of it as about $500 to do a PCI. Another $75-ish to do atherectomy. In the U.S. In the U.S., yeah. And Shockwave presently is still 500. You don't get incremental payment. The after the CPT panel last year voted in favor of a Category 1 CPT code for IVL. The next step in the process is that the RUC committee then goes and surveys physicians to determine what the RVUs are, when they sort of, basically, how much work do they do when they do a Shockwave case. And that will feed back into the system and determine what physicians will get paid incremental to that stent procedure. And we'll know what is proposed here in the next few months, sort of, July timeframe. We should have both the proposed rule for outpatient and the proposed rule for CPT, both of which would affect 2024. We'd be speculating if we said where we thought we would, the physician payment would land. Thank you. Yep. Very, very happy we made it through reimbursement without Rob. Our next question comes from Cecilia Furlong with Morgan Stanley. Please proceed with your question. Great. Good afternoon, thanks for taking the questions. I wanted to focus on Germany, some of the strength that you talked about seeing there post the reimbursement update. Just your outlook really for increasing the sales force there, your presence there, and then also your comments on penetration, where it is today, very low relative to Western European countries. How you think about that ramping over time, and where you ultimately look at penetration falling over the next several years? Yeah, sure. Thanks for the question, Cecilia. Let's see. We will probably double our sales force in Germany this year. That's already underway, and that's really to handle the higher volume and demand we expect on coronary with the DRG change. That's in process now. We've got a number of programs established and using some of the things we learned in the U.S., particularly on the peripheral reimbursement uplift, on how to go re-educate hospitals and on the change in reimbursement. Right now in Germany, IVL is, you know, it hasn't been reimbursed sufficiently for five years, and you have to undo that perception. That's part of the work the team it will do this year, next year. You know, when you look at the penetration in Germany, there's about 330,000 PCIs, and we were about 1% penetrated as we exited last year, despite having a really good, strong direct sales force in the country. I think, you know, if you look at that compared to where we are in Western Europe and in the U.S., you know, I think they can be, they could be our second or third highest penetrated country eventually. That would be, you know, with Japan and the U.S., I would expect, you know, kind of be the three highest penetrated countries based on the economics in place. The economics that will be in place or already are in place, and the fact that we have direct sales teams there that execute very well. I think, you know, over the next two, three years, Germany's got a lot of upside. It's, we're looking forward to seeing how much it is. Great. If I could follow up as well, just on BTK, some of your comments on just the interplay really between S4 and M5+ now, what you've seen recently, then just any updates too for S4 specifically and potentially up mapping from an APC standpoint. Thanks for taking the questions. Yeah. I'll work backwards. CMS continues to collect data for through our BTK C codes that we already have in place. As a reminder, BTK procedures are pay more than the ATK procedures. A straight angioplasty below the knee pays $10,000, and an IVL case or atherectomy above the knee pays $10,000. The payment levels are all sort of $5,000 higher than they are above the knee. Right now, we are reimbursed the same above the knee and below the knee, whereas atherectomy is paid higher below the knee. Our hope eventually is to land in that higher APC level, although the current payment below the knee is not cited nearly as often by customers as to why they would not use Shockwave as it was above the knee. Above the knee is a more economically sensitive vessel bed. Payment is perfectly adequate below the knee. We'd be happy if it was higher and hopefully over time, as Medicare CMS accumulates more data, they'll move us there. We don't we're not anticipating that will be happening this year and TBD about next year. The what might help that is that M5 plus is getting used at a increasing rate below the knee. The longer treatment length, faster pulses, longer catheter shaft are all being very well received by our customers. We have a relevant increase in utilization of the 3.5 mm and the 4 mm outer diameter lengths of our M5+ SKU matrix that indicate that we are starting to see a nice complement to the S4 device. We're. Since that currently is at a higher price that could order long-term to the benefit of the levels as CMS looks at the overall cost of the procedure. It does seem highly complementary to S4 at this juncture. As we move towards our investor day later this year, you'll see that below the knee is a meaningful focus for us on a couple of our upcoming product launches in the next two years. Great. Thank you. Thank you. Our next question comes from Imron Zafar with Deutsche Bank. Please proceed with your question. Hi, good afternoon, guys. Thank you so much for taking my question, and congratulations on a great quarter. I wanted to first ask about gross margin. Obviously another very strong first quarter. When you look out over the next two to three years, can you just talk about the sustainability of these levels? Just talking about, you know, the moving parts, geographic mix, direct versus distributor, and then Costa Rica coming on board at some point, next few quarters. Can you just talk about your ability to maintain this sort of high 80s gross margin longer term? Thanks. Yeah, we're. You highlighted a couple of the puts and takes. As China grows, that's great for the top line, unhelpful on the gross margin side. Japan, where we are direct, and we're not paying sort of distributor transfer price, that's a nice counterbalance to China in terms of the international contribution to gross margin, and same with Germany. U.S. is the strongest contributor to gross margin, given reimbursement and pricing advantages to the U.S. system. We envision U.S. will continue its really healthy growth rate into the future. Product mix, we don't envision any meaningful negative or positive contribution from the product mix. Often when we launch a new product such as L6, as we're working out the kinks, it is higher cost as we figure out how to optimize fixtures and processes and the like, and we're in the process of doing that right now with L6. But over time, that'll resemble where we are with other products in terms of gross margin. Then we'll move that to Costa Rica once we sort of work through the optimization process. Costa Rica, the facility, our facility won't be contributing until the back half of next year, which is when we sort of should start shipping product from there. I wouldn't model a meaningful change to our gross margin from Costa Rica, although there is potential upside given given the better labor and overhead that we'll see out of that facility. Okay. Thank you. Just one quick one on the pipeline. Any updates on when we might see some initial human data from the mitral and/or aortic IVL catheters? We will, when we put our roadmap out in October at our October 23rd event, we should give you a sense of when we're gonna be in the clinic at least with aortic. Mitral, it's in the clinic right now off-label when people do a case here or there using our peripheral catheter. We're still exploring what the right way to, if there's a way for Shockwave to participate in mitral. Great. Thank you so much. Our next question comes from Mike Matson with Needham. Please proceed with your question. Yeah, good afternoon. Thanks for taking my questions. I wanna ask another one on the below the knee opportunity. Some of the feedback that we've gotten is that the S4 catheter, while it can get below the knee, it's a little on the large side. You mentioned you've got some things in your pipeline there, but I was just wondering if you're planning on like an XS, extra small catheter or something that can go deeper into the, you know, ankle region and, you know, when we could maybe see that, if you can even make the balloon small enough to fit down there. We're always trying to find ways to make our systems sort of more deliverable. What we hear on Shockwave S4 more often, much more often, is they wish it was longer, which is why they're starting to deploy Shockwave M5+ down below the knee. I think when you as we lay out our BTK portfolio, 'cause it's really gonna be a portfolio of multiple products to treat the variety of vessels and diseases below the knee, I think we're quite encouraged that what has been a nice business but under-penetrated more than any other vessel beds that we treat. We think BTK is gonna be a really nice contributor starting in 2024. Okay. Got it. I just wanna ask one on the tax rate. I don't know if you're willing to give us any sort of guidance for the year. It did come in significantly below what I've been modeling, which is kind of the 25% range. I don't know where you're at in terms of starting to pay sort of a full tax rate, but I thought it might be this year. I gotta say, I was so worried Trinh wasn't gonna get to answer a question. I'm so glad you asked. Yes. It's still safe to model 25%. We're still burning through our NOL, so from a cash outflow, it'll be less. This quarter in particular was low because we had some discrete items, differences between book and tax that's causing the rate. It's, from a modeling perspective, 25% is what we expect. Okay. Got it. Thank you. All right. I think that's a wrap. Thanks everybody for your time and attention. Thank you, Mike, particularly for asking Trinh a question. Much appreciated. We all miss Dan, but Trinh crushed it. Thanks very much. Have a good day. This concludes today's conference. Thank you for your participation. You may disconnect your lines at this time.